Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
What are the in situ effects of multi site
2025-02-25

What are the in-situ effects of multi-site CaM associations with AT1R? Kai et al. showed that synthetic peptides corresponding to residues 125–137 (rat sequence) in SMD2, 217–227 in the N-terminal side of SMD3, and 304–316 in SMD4JM inhibit to various degrees AngII-induced GTPase activity of isolate
-
Since HETEs and lipoxins the downstream products of LOX from
2025-02-25

Since HETEs and lipoxins, the downstream products of 12/15-LOX from AA, may alter cellular proliferation and apoptosis,31, 32 and possibly explain the increase of tumour progression and metastasis. However, we here found that HETEs did not affect the proliferation of melanoma in vitro. This may part
-
An important observation is that this patient has been
2025-02-25

An important observation is that this patient has been on ALK inhibitor for more than 4 years (51 months: 27 months on crizotinib+24 months on alectinib and on-going) and there was no evidence of disease progression in the central nervous system. The other potential driver mutation in this patient’s
-
In our previous study we showed that normal and
2025-02-25

In our previous study we showed that normal and cancerous Amikacin of kidney exhibit the activity of alcohol dehydrogenase and aldehyde dehydrogenase. Furthermore, the activity of class I ADH isoenzymes and total ADH were significantly higher in cancer tissue than in unchanged renal cells. Moreover
-
In terms of the full length proteins it was noted
2025-02-25

In terms of the full-length proteins, it was noted early on that ACs have two cellular localizations: as integral proteins of the plasma membrane and as soluble proteins in the cytosol. Based on the distribution in mammalian sequences, it was initially proposed that subclass IIIa contains only membr
-
We investigated the role of ABT treatment in
2025-02-25

We investigated the role of ABT 702 treatment in MAPKinase activation in mouse microglia in vitro. In Fig. 7D immunocytochemistry results revealed that Iba1 and p-ERK1/2 co-localized in LPS induced mouse microglia. In our previous study we have reported that LPS activates ERK1/2 phosphorylation (Ahm
-
Patients with ADA SCID may experience autoimmune
2025-02-25

Patients with ADA-SCID may experience autoimmune AEs after SCT (and/or during ERT) that are thought to be related to immune dysregulation prior to achieving complete immune reconstitution. The more common autoimmune manifestations include hemolytic anemia, hypothyroidism, and immune thrombocytopenia
-
False positivity of Anti AChR Ab titers due to
2025-02-25

False positivity of Anti-AChR Ab titers, due to cross reactivity with bungarotoxin, has previously been demonstrated. One such study reported that patients with amyotrophic lateral sclerosis, who had received long term snake venom therapy, had developed antibodies to bungarotoxin and hence demonstra
-
br Methods br Results From a study population of
2025-02-25

Methods Results From a study population of 7069 patients, a total of 149 falls were reported during the study 5-Ethylthio-1H-tetrazole RNA synthesis for an incidence rate (IR) of 5.2 falls per 1000 patient-days (PD), 95% confidence interval (CI) 4.4/1000 PD–6.1/1000 PD. The incidence rate rati
-
br lipoxygenase pathway in brain aging and alzheimer s disea
2025-02-25

5-lipoxygenase pathway in Resin for drug discovery aging and alzheimer’s disease 5LO is found throughout the central nervous system, in both neuron and glia cells (Farias et al., 2007). However, its expression levels are highest in the cortex and hippocampus areas, two regions that are particular
-
Normally the activity of the lyase increases with the onset
2025-02-25

Normally, the activity of the 17,20-lyase increases with the onset of adrenarche [7], [8], [15]. Adrenarche has previously been perceived as a relatively sudden event, occurring physiologically between 6 and 8years of age. However, results from our laboratory clearly indicated that adrenarche is a c
-
Autophagy is finalized through the coordinated
2025-02-24

Autophagy is finalized through the coordinated positioning and fusion of autophagosomes with lysosomes, during which an array of common and specific membrane traffic-associated proteins is mobilized. Among these proteins, small GTPases, like Rab7, Rab34, or Arl8, and their encorafenib proteins, reg
-
shows the complexes resulting from interaction of the
2025-02-24

shows the complexes resulting from interaction of the proposed anion receptors with the anions F, Cl, NO, and SO. No imaginary frequency was observed for the optimized complexes indicating the complexes are in potential minima and they are not transition state structures. summarizes the calculated
-
Crystal structures were obtained of sulfonamide
2025-02-24

Crystal structures were obtained of sulfonamide 18 and amide 19 as a derivative of amide 36 (Fig. 7A and B). The precise rotameric orientation of amide 36 was of significant interest to understand the compound's interaction with the protein. As it would be difficult to assign the rotomer of 36, the
-
br Acknowledgements M M M is the William
2025-02-24

Acknowledgements M.M.M. is the William Dow Lovett Professor of Neurology and is supported by grants from the Michael J. Fox Foundation for Parkinson's Research, the American Parkinson Disease Association, the New Jersey Health Foundation/Nicholson Foundation, and by the National Institutes of Hea
15772 records 22/1052 page Previous Next First page 上5页 2122232425 下5页 Last page